sapraa.org.za - /presentations/March2012/MCC presentation/

[To Parent Directory]

 3/29/2012  2:18 PM       377344 2.25_PA_CTD_Jun11_v3.doc
 3/29/2012  2:17 PM        13250 32R141.docx
 3/29/2012  2:32 PM      4218825 5x5.wmv
 3/29/2012  2:15 PM        24576 AMENDMENT SUBMISSIONS FORMAT POINT 2.doc
 3/29/2012  2:15 PM        11355 API report of comparative study.docx
 3/29/2012  2:15 PM        15113 Appendix A2 Example.docx
 3/29/2012  2:16 PM        18499 AS EXAMPLE PERFECT CURE 500 mg.docx
 3/29/2012  2:16 PM        12797 CEP re as per guidelines.docx
 3/29/2012  2:16 PM        11398 Comprehensive TOC.docx
 3/29/2012  2:16 PM        15082 Copy of 12.03.20 P & A additional Comments (3).xlsx
 3/29/2012  2:16 PM        13129 Cover letter section 6.docx
 3/29/2012  2:16 PM        11802 CTD stability data.docx
 3/29/2012  2:15 PM       252416 CTD vs MRF1 vs MBR1_5_Hilde.doc
 3/29/2012  2:11 PM        39730 cTOC for MRF1 to CTD transition example.docx
 3/29/2012  2:12 PM       150016 EXAMPLE APPLICATION FORM.doc
 3/29/2012  2:12 PM        69632 Example Pharma Pty Ltd.doc
 3/29/2012  2:12 PM        14693 EXAMPLE PHARMACEUTICALS cover page of submission.docx
 3/29/2012  2:12 PM        14328 EXAMPLE PRODUCT, 12345 CTD update.docx
 3/29/2012  2:12 PM        13508 MCC Contact Information.docx
 3/29/2012  2:13 PM        13353 PART B Module 1.docx
 3/29/2012  2:11 PM        36824 PERFECT CURE 500 mg cTOC EXAMPLE.docx
 3/29/2012  2:09 PM      6931109 SOMEONE SHOULD TELL THIS GIRL THIS CANT BE DONE.wmv
 3/29/2012  1:48 PM      2466655 Tabs used in CTD submissions.pptx
 3/29/2012  1:41 PM        31863 TOC WORKING DOC.docx
 3/29/2012  1:41 PM      4053605 winter_Alles_Rutscht.wmv
 3/29/2012  1:13 PM       482816 za ctd 9 months later.ppt